(+/-)-N-cyclohexyl-2-(2-(2-methoxy-4-morpholinophenylamino)-7-(4-methoxybenzyl)-5-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-ylamino)benzenesulfonamide | 1312163-90-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: (+/-)-N-cyclohexyl-2-(2-(2-methoxy-4-morpholinophenylamino)-7-(4-methoxybenzyl)-5-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-ylamino)benzenesulfonamide
• 英文别名: N-cyclohexyl-2-[[2-(2-methoxy-4-morpholin-4-ylanilino)-7-[(4-methoxyphenyl)methyl]-5-methyl-5,6-dihydropyrrolo[2,3-d]pyrimidin-4-yl]amino]benzenesulfonamide
• CAS: 1312163-90-8
• 化学式: C₃₈H₄₇N₇O₅S
• 分子量: 713.901
• InChiKey: RKJDABDWWFAJCI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.3
• 重原子数：
  51
• 可旋转键数：
  12
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  139
• 氢给体数：
  3
• 氢受体数：
  12

文献信息

• TREATMENT OF DISEASES BY EPIGENETIC REGULATION
  申请人：McLure Kevin G.

  公开号：US20130281397A1

  公开（公告）日：2013-10-24

  The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of cancer, including NUT midline carcinoma, Burkitt's Lymphoma, Acute Myelogenous Leukemia, and Multiple Myeloma; autoimmune or inflammatory diseases or conditions, and sepsis.

  本公开提供了抑制溴结构域和额外末端结构域（BET）蛋白的非天然存在的多酚化合物。所公开的组合物和方法可用于治疗和预防癌症，包括NUT中线癌、Burkitt淋巴瘤、急性髓系白血病和多发性骨髓瘤；自身免疫或炎症性疾病或症状，以及败血症。
• 2,4-DIAMINO-6,7-DIHYDRO-5H-PYRROLO[2,3]PYRIMIDINE DERIVATIVES AS FAK/Pyk2 INHIBITORS
  申请人：Xiao Dengming

  公开号：US20130281438A1

  公开（公告）日：2013-10-24

  The invention relates to a novel class of 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as a FAK and/or Pyk2 inhibitor, to a process for their preparation, and to a composition thereof, as well as to use of the compounds for the inhibiting FAK and/or Pyk2 and method for the treatment of a FAK and/or Pyk2 mediated disorder or disease.

  本发明涉及一种新型的2,4-二氨基-6,7-二氢-5H-吡咯[2,3]嘧啶衍生物，作为FAK和/或Pyk2抑制剂，以及它们的制备方法、组合物和化合物用于抑制FAK和/或Pyk2以及治疗FAK和/或Pyk2介导的疾病或疾病的方法。
• COMPOSITIONS AND THERAPEUTIC METHODS FOR ACCELERATED PLAQUE REGRESSION
  申请人：LEBIODA Kenneth Eugene

  公开号：US20160346291A1

  公开（公告）日：2016-12-01

  The invention comprises methods for treating and/or preventing cardiovascular, cholesterol, and lipid related disorders, including atherosclerosis, through-co-administration of therapeutically effective amounts of a compound of Formula I or a pharmaceutically acceptable salt thereof and rosuvastatin or pravastatin or a pharmaceutically acceptable salt of rosuvastatin or pitavastatin. The invention further provides compositions comprising a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of or pitavastatin or a pharmaceutically acceptable salt of rosuvastatin or pitavastatin.
• US9428508B2
  申请人：——

  公开号：US9428508B2

  公开（公告）日：2016-08-30